Results 1 to 10 of about 15,630 (215)

Clinical and Economic Value of a Biosimilar Portfolio to Stakeholders: An Integrative Literature Review [PDF]

ClinicoEconomics and Outcomes Research
Grace E Fox,1 Mark Bernauer,1 Jennifer M Stephens,1 Bianca Jackson,1 Joshua A Roth,2 Ahmed Shelbaya2,3 1Strategic Market Access, OPEN Health, Bethesda, MD, USA; 2Global Access and Value, Pfizer Inc., New York, NY, USA; 3Department of Epidemiology ...
Fox GE, Bernauer M, Stephens JM, Jackson B, Roth JA, Shelbaya A   +5 more
doaj   +1 more source

Biosimilar medicines and cost-effectiveness

ClinicoEconomics and Outcomes Research, 2011
Steven SimoensResearch Centre for Pharmaceutical Care and Pharmaco-economics, Faculty of Pharmaceutical Sciences, Katholieke Universiteit Leuven, Leuven, BelgiumAbstract: Given that biosimilars are agents that are similar but not identical to the ...
Steven Simoens
doaj   +2 more sources

Ten years' clinical experience with biosimilar human growth hormone: a review of efficacy data

Drug Design, Development and Therapy, 2017
Juan Pedro López-Siguero,1 Roland Pfäffle,2 Philippe Chanson,3 Mieczyslaw Szalecki,4,5 Nadja Höbel,6 Markus Zabransky6 1Servicio de Endocrinología Pediátrica, Hospital Materno-Infantil, Hospital Regional Universitario de M&
López-Siguero JP, Pfäffle R, Chanson P, Szalecki M, Höbel N, Zabransky M   +5 more
doaj   +1 more source

Long-term safety and efficacy of biosimilar infliximab among patients with inflammatory arthritis switched from reference product

Open Access Rheumatology: Research and Reviews, 2017
Abuelmagd Abdalla, Niamh Byrne, Richard Conway, Thomas Walsh, Geraldine Mannion, Michael Hanly, Miriam O’Sullivan, Ann Maria Curran, John J Carey Department of Rheumatology, Galway University Hospitals, Galway ...
Abdalla A, Byrne N, Conway R, Walsh T, Mannion G, Hanly M, O'Sullivan M, Curran AM, Carey JJ   +8 more
doaj   +1 more source

Patent and Regulatory Landscape of Biosimilars in the United States and Europe: Implications for Advancing the Domestic Biosimilar Industry with a Focus on Anti-TNF-α Biopharmaceuticals

Journal of Intellectual Property
Biopharmaceuticals exhibit excellent therapeutic efficacy; however, their high cost remains a significant limitation. The introduction of biosimilars is expected to enhance market competition and reduce biopharmaceutical prices.
Tae-Kwon Kim, Tai-Hyun Kang
doaj   +1 more source

Uptake of biosimilars in China: a retrospective analysis of the case of trastuzumab from 2018 to 2023

Global Health Research and Policy
Background The Chinese biosimilar industry has demonstrated rapid growth in recent years. Limited evidence is available about biosimilar uptake at the national level.
Qiyou Wu, Zhitao Wang, Yihan Fu, Ren Luo, Jing Sun   +4 more
doaj   +1 more source

Biosimilar medicines: creating sustainable competition in an era of a new patent cliff in biological medicines

Journal of Pharmaceutical Policy and Practice, 2015
Maarten Van Baelen
doaj   +1 more source

A cost-effectiveness evaluation of the originator follitropin alpha compared to the biosimilars for assisted reproduction in Germany

International Journal of Women's Health, 2019
Weiguang Xue,1 Adam Lloyd,1 Edel Falla,1 Claudia Roeder,2 Rudiger Papsch,2 Klaus Bühler3,41IQVIA, Real-World Evidence, London, UK; 2Merck KGaA, Frankfurt, Germany; 3Centre for Gynecology Endocrinology & Reproductive Medicine Kinderwunsch-Zentrum
Xue W, Lloyd A, Falla E, Roeder C, Papsch R, Bühler K   +5 more
doaj  

Public deliberation to assess patient views on biosimilar medication switching for the treatment of inflammatory bowel disease

BMC Health Services Research
Background Biosimilars are highly similar, but not identical, versions of originator biologic medications. Switching patients to biosimilars presents an opportunity to mitigate rising drug costs and expand patient access to important biologic therapies ...
Kerry A. Ryan, Shirley Cohen-Mekelburg, Jessica A. Baker, Eileen M. Weinheimer-Haus, Chris Krenz, Jason K. Hou, Raymond De Vries, Akbar K. Waljee   +7 more
doaj   +1 more source

Real-World Analysis of Switching Between Ranibizumab Biosimilars: Safety and Results - a Multicenter Retrospective Observational Study. [PDF]

Clin Ophthalmol
Chakraborty D, Sinha TK, Biswas RK, Maiti A, Barman MJ, Bhattacharya R, Boral S, Das A.   +7 more
europepmc   +1 more source